Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the LifeSci Partners Genetic Medicines Summit
PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the LifeSci Partners Genetic Medicines Summit on Tuesday, June 22, 2021, at 2:00 p.m. ET.
To access the live webcast, please visit the “Investors and News” section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/.
About Oyster Point Pharma
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases.
Investor Contact:
Tim McCarthy
LifeSci Advisors, LLC
(212) 915-2564
investors@oysterpointrx.com
Media Contact:
Sheryl Seapy
Real Chemistry
(213) 262-9390
sseapy@realchemistry.com
